References
- Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Jr, et al. Predicting sustained virologic responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–33
- Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Austrian Hepatitis Study Group. Gastroenterology 2008; 135: 451–8
- Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46: 1688–94
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–52
- Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, et al. for the Austrian Hepatitis Study Group. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006; 44: 275–82